205 related articles for article (PubMed ID: 26867596)
1. Inhibition of cancer cell growth by ruthenium complexes.
Iida J; Bell-Loncella ET; Purazo ML; Lu Y; Dorchak J; Clancy R; Slavik J; Cutler ML; Shriver CD
J Transl Med; 2016 Feb; 14():48. PubMed ID: 26867596
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
3. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
5. A Review of Ruthenium Complexes Activities on Breast Cancer Cells.
Popolin CP; Cominetti MR
Mini Rev Med Chem; 2017; 17(15):1435-1441. PubMed ID: 28176627
[TBL] [Abstract][Full Text] [Related]
6. New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.
Bratsos I; Simonin C; Zangrando E; Gianferrara T; Bergamo A; Alessio E
Dalton Trans; 2011 Oct; 40(37):9533-43. PubMed ID: 21853191
[TBL] [Abstract][Full Text] [Related]
7. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium(II)-Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells.
Stephens LJ; Levina A; Trinh I; Blair VL; Werrett MV; Lay PA; Andrews PC
Chembiochem; 2020 Apr; 21(8):1188-1200. PubMed ID: 31701616
[TBL] [Abstract][Full Text] [Related]
9. Dual FGFR-targeting and pH-activatable ruthenium-peptide conjugates for targeted therapy of breast cancer.
Franco Machado J; Sá M; Pires I; da Silva MT; Marques F; Coelho JAS; Mendes F; Piedade MFM; Machuqueiro M; Jiménez MA; Garcia MH; Correia JDG; Morais TS
Dalton Trans; 2024 May; 53(18):7682-7693. PubMed ID: 38573236
[TBL] [Abstract][Full Text] [Related]
10. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
11. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.
Pereira SAP; Romano-deGea J; Barbosa AI; Costa Lima SA; Dyson PJ; Saraiva MLMFS
Dalton Trans; 2023 Aug; 52(33):11679-11690. PubMed ID: 37552495
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex [(η6-p-MeC6H4Pri)2Ru2(μ-S-p-C6H4OH)3]Cl.
Muthná D; Tomšík P; Havelek R; Köhlerová R; Kasilingam V; Čermáková E; Stíbal D; Řezáčová M; Süss-Fink G
Anticancer Drugs; 2016 Aug; 27(7):643-50. PubMed ID: 27187018
[TBL] [Abstract][Full Text] [Related]
13. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
[TBL] [Abstract][Full Text] [Related]
14. Arene ruthenium(ii) complex, a potent inhibitor against proliferation, migration and invasion of breast cancer cells, reduces stress fibers, focal adhesions and invadopodia.
Wu Q; He J; Mei W; Zhang Z; Wu X; Sun F
Metallomics; 2014 Dec; 6(12):2204-12. PubMed ID: 25142071
[TBL] [Abstract][Full Text] [Related]
15. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
16. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.
Yang L; Zhang J; Wang C; Qin X; Yu Q; Zhou Y; Liu J
Metallomics; 2014 Mar; 6(3):518-31. PubMed ID: 24336978
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes.
Grozav A; Balacescu O; Balacescu L; Cheminel T; Berindan-Neagoe I; Therrien B
J Med Chem; 2015 Nov; 58(21):8475-90. PubMed ID: 26488797
[TBL] [Abstract][Full Text] [Related]
18. Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]
Purushothaman B; Arumugam P; Ju H; Kulsi G; Samson AAS; Song JM
Eur J Med Chem; 2018 Aug; 156():747-759. PubMed ID: 30048924
[TBL] [Abstract][Full Text] [Related]
19. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
Barry NP; Edafe F; Therrien B
Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
